Royalty Report: Medical, Device, Therapeutic – Collection: 2747


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Medical
  • Device
  • Therapeutic
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 2747

License Grant
The Licensee entered into the License Agreement to obtain exclusive rights to the undisclosed Licensor's technology relating to the treatment of kidney failure, congestive heart failure and other medical diseases, with no geographic restrictions, that will last for a period of ninety-nine years or until the expiration of its proprietary rights in each item of intellectual property, if earlier.
Field of Use
The rights granted apply to the healthcare industry.

As a result, the Licensee has become a developmental stage company focused on researching, developing, and commercializing technology and products related to the treatment of kidney failure and congestive heart failure.

IPSCIO Record ID: 5800

License Grant
Licensor hereby grants to Licensee, with right to grant subLicenses, the sole and exclusive license to use, improve, expand and otherwise exploit the Technology, to make, use, and sell the Licensed Products, and otherwise to practice the inventions and the art that is embodied or described in the Licensor Patents, the Licensor Patent Applications, and any improvements thereto made in whole or in part by Licensor in connection with the Technology provided.
License Property
Licensed Products means all products based on or derived from the Technology and any products sold in connection with the use of such products, including, but not limited to the Wearable Kidney and all related devices, whether now-existing or hereafter developed, that where sold, would infringe or misappropriate one or more of Licensor’s Intellectual Property Rights or Know-How, including, without limitation, the Licensor Patents or Licensor Patent Applications.

Technology relates to the treatment of kidney failure and congestive heart failure, with no geographic restrictions, that will last for a period of ninety-nine years or until the expiration of its proprietary rights in each item of intellectual property, if earlier.

Field of Use
We acquired the rights to our Congestive Heart Failure (CHF) treatment products, Wearable Artificial Kidney, and other medical devices.  The Field of Use relates to the healthcare industry.

IPSCIO Record ID: 3690

License Grant
The Licensee entered into a Contribution Agreement with an undisclosed company whose sole managing member is their current Chairman. We issued 9,600,000 shares of common stock in exchange for (a) all of our right, title, and interest to the name Xcorporeal and related trademarks and domain names, and the right to enter into the Merger Agreement and License Agreement dated September 1, 2006 pursuant to which the Licensee obtained the exclusive rights to the technology relating to congestive heart failure treatment, kidney failure treatment, and other medical devices.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 3209

License Grant
The License agreement grants an exclusive license to all technology relating to the Company's Wearable Artificial Kidney and other medical devices, with no geographic restrictions.

IPSCIO Record ID: 2997

License Grant
The undisclosed Licensor is committed under a Novacor LVAS royalty Agreement, to make royalty payments to certain employees on Novacor LVAS implant kits and related peripheral equipment and services.
License Property
Novacor® LVAS is an implanted, wearable system that provides long-term pulsatile circulatory support for patients with life-threatening heart failure.  The Novacor LVAS, a pump implanted alongside the patient's own heart to  take over a large portion of the workload of the natural heart, supports end- stage heart failure patients. It is an electrically powered, pulsatile flow  device.

We continue to support our Novacor patients but have discontinued the manufacture and sale of the Novacor LVAS. We do not anticipate any Novacor product revenues in 2010.

Field of Use
The Field of Use is focused on the development and sale of ventricular assist devices.

IPSCIO Record ID: 3096

License Grant
The Licensee entered into an exclusive royalty-based license agreement with a University which granted the Licensee an exclusive right to certain inventions, patents and patent applications.
Field of Use
The Licensee develops Ventricular Assist Devices.  A ventricular assist device (VAD), is a mechanical circulatory device that is used to partially or completely replace the function of a failing heart. Some VADs are intended for short term use, typically for patients recovering from heart attacks or heart surgery, while others are intended for long term use (months to years and in some cases for life), typically for patients suffering from congestive heart failure.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.